Similar to DKC, aplastic anemia associated with CRMCC can be cured only by hematopoietic SCT (HSCT); however, to date HSCT has not been widely used in this patient population. 4, 7, 8 Herein, we report a case of CRMCC associated with a TINF2 mutation, which was successfully treated with HSCT using a fludarabine-based reduced-intensity conditioning (RIC) regimen.
The patient was a Japanese boy who was born at 38 weeks gestation to non-consanguineous parents and had a birth weight of 2.57 kg (À0.8 s.d.). There was no family history of ocular or neurological disease. The neonatal period was uneventful and his development was considered normal until 1 year of age. Nail dystrophy was noted, but he displayed no signs of leukoplakia or skin disease. At the age of 15 months, his mother first noticed a right divergent squint. Subsequent ophthalmological investigation revealed bilateral exudative retinopathy and retinal detachment, consistent with bilateral Coats' disease ( Figure 1a ). Truncal ataxia with normal deep-tendon-and superficial-skin-reflexes was noted on neurological examination. At the age of 17 months, brain computed tomography (CT) scanning demonstrated extensive intracranial calcifications. T2-weighted magnetic resonance imaging of the brain revealed spotty high signals within the white matter of the brainstem, the deep gray nuclei, and the right frontal and parietal lobes (Figure 1b and c) . A cystic mass adjacent to the thalamus was also observed. Macrocytic anemia and severe thrombocytopenia were also detected (red blood cell, 301 Â 10 4 per mL; hemoglobin level, 9.8 g/dl; mean corpuscular volume (MCV), 98.3 fl; reticulocyte count: 37 000 per mL; platelet count: 8000 per mL). No leukopenia or neutropenia was observed (white blood cell, 5100 per mL with an ANC of 1479 per mL). BM aspiration revealed hypoplastic BM (nucleated cell count: 41 500 per mL and megakaryocytes 0 per mL, with no dysplastic features). G-banding analysis of the BM at 18 months revealed the karyotype 48, XY, þ 2 mar (1/16)/46, XY (15/16). A chromosomal breakage study showed no excess of mitomycin C-induced breaks, which indicated that Fanconi's anemia was not present (data not shown). Flow-FISH analysis in PBLs demonstrated shortened telomere length and DNA sequencing identified a heterozygous missense mutation (845 G4A, R282H) of the TINF2 gene (Figure 1d ). TINF2 encodes TIN2, one of the key components of shelterin, a protein complex that stabilises telomeres. 7 Mutated amino acids were tightly clustered in the position between 280 and 290 in classic DKC or CRMCC patients. 7, 8 On the basis of these findings, a diagnosis of CRMCC was made. At the age of 17 months, the exudative retinopathy was successfully treated with laser coagulation, pars plana vitrectomy and the intra-vitreal administration of vascular endothelial growth factor inhibitors. However, at the age of 22 months, the bicytopenia became more severe and treatment with prednisolone (1 mg/kg/day) and danazol (5 mg/kg/day) was initiated. In response, the anemia improved slightly, but there was no effect on the thrombocytopenia, although bleeding tendency was not evident. Thus, we decided to perform allogeneic HSCT with an HLA-matched, related, healthy female donor. The conditioning regimen was as follows: 25 mg/m 2 fludarabine daily on days À5 to À2; 25 mg/kg CY daily on days À5 to À2 and 1.25 mg/kg antithymocyte globulin (Thymoglobulin) daily on days À5 to À2. Total nucleated cell and CD34 þ doses were 2.48 Â day 48. Genotyping using XY-FISH analysis of a BM sample taken at day 48 revealed that 98.4% of total nucleated cells were of donor origin. The post-transplant course was uneventful with grade 1 oral mucositis being the only complication. Neither acute nor chronic GVHD was evident. The patient is currently 20 months post transplant without any immunosuppressants and transplantation-related complication.
In surveying the literature, we found that in CRMCC, 1 --9 at least one of the DKC triad of dystrophic nail, abnormal skin findings and leukoplakia was noted significantly more frequently in positive vs negative hematological disorder (one of DKC triad, 10/17 vs 5/23, Po0.01; dystrophic nail, 9/16 vs 4/23, Po0.01; leukoplakia, 3/5 vs 0/9, Po0.05). We found two previous reports of CRMCC patients with an identical mutation in TINF2 to that in our patient. 7, 8 Kajtar et al. 4 described a 2-year-old girl with CRMCC successfully treated with allogeneic BMT from an HLA-identical brother. The post-transplantation course in this patient was uneventful with only mild GVHD. Savage et al.
7 described a case of CRMCC who died after BMT; however, detailed information on the conditioning regimen was not available. Walne et al. 8 also described four cases of CRMCC with a TINF2 mutation, of which one received BMT, but details on the conditioning regimen and transplantation courses were not reported. In DKC, circulating lymphocytes and fibroblasts exhibit an increased in vitro sensitivity to radiation and alkylating agents. 10 Therefore, this suggested that HSCT using myeloablative conditioning regimens in DKC patients would be associated with high regimen-related toxicity. 10 For this reason, RIC regimens are strongly recommended in HSCT for DKC patients. 11 Herein, we used a RIC regimen for our patient, which was safe and had minimal toxicity. Our experience suggests that HSCT with a RIC regimen should be considered for treatment of CRMCC patients with hematological disorders.
